Haitao Guo
Principal Scientist Abbvie
Dr. Haitao Guo is a Principal Scientist at AbbVie, where he leads discovery programs advancing next generation therapeutics for autoimmune diseases, including IBD. With over a decade of experience spanning inflammation, infectious diseases, immunometabolism, and translational biomarker discovery, he has driven programs from target identification through IND-enabling studies. His work, published in Nature Immunology, Cell Host & Microbe, and Nature Medicine, has revealed key immune-regulatory mechanisms underlying inflammation and tolerance. Prior to joining AbbVie’s Discovery group, Dr. Guo served as an Assistant Professor at the University of North Carolina.
Seminars
Wednesday 1st April 2026
Characterizing Pathogenic Cell Populations in Non-Responder IBD Tissues to Inform Targeted Therapeutic Development
2:00 pm
- Characterize pathogenic cell types and molecular factors enriched in non-responder IBD tissues to uncover mechanisms driving treatment resistance
- Leverage tissue-level cellular insights to identify potential therapeutic targets aimed at restoring response or achieving durable remission
- Discuss methodological approaches for profiling non-responder tissues and building a framework linking tissue and blood biomarkers to predict clinical outcomes
